Bristol Myers Squibb Reports Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis

Bristol Myers Squibb today announced positive results from the Phase 3 POETYK PSA-1 and PSA-2 trials evaluating deucravacitinib (Sotyktu) in adults with active psoriatic arthritis. Both trials met their primary endpoints, with significantly more patients achieving ACR20 response at week 16 compared to placebo.